ResearcherSecond Affiliated Hospital of Zhejiang UniversityActive in the last 2 years

Long Liu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5130088086. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2026: 2 papers

Papers 2

OGT-mediated O-GlcNAcylation of BICD2 drives gemcitabine resistance in pancreatic cancer via accelerating G2/M cell cycle progression. Co-author DOI 10.1016/j.drup.2026.101469 ↗
Vaccinia-related kinase 2 inhibition elicits vulnerability of glutathione metabolism in pancreatic cancer. Co-author DOI 10.1038/s41419-026-08573-9 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Zhiyu Li · 1 shared paper, 2026 · strength 0.30
- Paper Vaccinia-related kinase 2 inhibition elicits vulnerability of glutathione metabolism in pancreatic cancer. DOI 10.1038/s41419-026-08573-9 ↗
Xiaowei Fu · 1 shared paper, 2026 · strength 0.30
- Paper Vaccinia-related kinase 2 inhibition elicits vulnerability of glutathione metabolism in pancreatic cancer. DOI 10.1038/s41419-026-08573-9 ↗
Sisi Chen · 1 shared paper, 2026 · strength 0.30
- Paper Vaccinia-related kinase 2 inhibition elicits vulnerability of glutathione metabolism in pancreatic cancer. DOI 10.1038/s41419-026-08573-9 ↗
Yu Zhang · 1 shared paper, 2026 · strength 0.26
- Paper OGT-mediated O-GlcNAcylation of BICD2 drives gemcitabine resistance in pancreatic cancer via accelerating G2/M cell cyc… DOI 10.1016/j.drup.2026.101469 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.